RxDoctor Payments DataLook up a doctor →

Stephanie Phillips, PA

Medical · Marlton, NJNPI 1710370135

Payments from drug & device makers

$11,726in general payments, 2019–2025

Across 754 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$735
  • AstraZeneca$650
  • Pfizer$546
  • Otsuka America Pharmaceutical, Inc.$462
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$11,711100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,726 in reported general payments places this provider in the 95th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey

Medicare billing

Part B allowed, 2024
$28,935
Medicare patients
152
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$37,297
JardianceEmpagliflozin23$22,838
LinzessLinaclotide30$19,382
OzempicSemaglutide12$19,310
Repatha SureclickEvolocumab11$17,563
RybelsusSemaglutide18$17,320
EliquisApixaban18$16,356
MounjaroTirzepatide11$11,519
BelsomraSuvorexant26$11,240
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,895
VascepaIcosapent Ethyl16$6,123
Atorvastatin Calcium231$2,749
Levothyroxine Sodium160$2,017
Rosuvastatin Calcium104$1,958
Omeprazole125$1,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$461$37,29760 claims
Novo NordiskOzempic, Rybelsus$1,118$36,63030 claims
Boehringer IngelheimJardiance$401$22,83823 claims
AbbVieLinzess$1,727$19,38230 claims
PfizerEliquis$546$16,35618 claims
Lilly USA, LLCMounjaro$462$11,51911 claims
MerckBelsomra$204$11,24026 claims
AstraZenecaBreztri Aerosphere$650$9,89516 claims
Almatica Pharma LLCSertraline Hcl$87$45033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 medical providers in New Jersey.

Other medical in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →